---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-25-000094"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:32:28.247703+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences Q3 revenue $402.1M, adjusted EPS $0.54; cuts full-year guidance

## Summary
- Q3 reported revenues $402.1M, +5.6% YoY; organic growth 5.0%.
- GAAP net loss $(5.4)M ($(0.07)/diluted share); adjusted EPS $0.54 vs $0.41 YoY.
- Codman Specialty Surgical revenues $292.6M (+8.1% reported); Tissue Technologies $109.5M (-0.5% reported).
- Full-year 2025 revenue guidance cut to $1.620B-$1.640B (organic growth -1.6% to -0.4%); adj EPS $2.19-$2.24.
- Relaunched PriMatrix and Durepair ahead of schedule; Braintree facility on track for production in June 2026.

## SEC filing metadata
- accession: 0000917520-25-000094
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752025000094/0000917520-25-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752025000094/iart-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-25-000094
- JSON: https://secwatch.observer/filing/0000917520-25-000094.json
- Plain text: https://secwatch.observer/filing/0000917520-25-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.